All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Longevity comparison

Humanin vs SS-31 (Elamipretide)

An educational, source-based comparison of Humanin and SS-31 (Elamipretide) — how each peptide works, what it's researched for, and what to know before going deeper.

Mitochondrial · Neuroprotection
Humanin

Mitochondrial-derived peptide studied for neuroprotection and metabolism.

Mechanism

A 24-amino-acid peptide encoded in mitochondrial DNA. Research suggests cytoprotective effects against Alzheimer's-related toxicity, improved insulin sensitivity, and modulation of apoptotic signaling.

Research areas
  • Neuroprotection (Alzheimer's models)
  • Insulin sensitivity
  • Cardiovascular protection in animal models
Considerations
  • Early-stage research.
  • No approved therapeutic use.
Full Humanin profile →
Mitochondrial
SS-31 (Elamipretide)

Cardiolipin-targeting peptide studied for mitochondrial dysfunction.

Mechanism

A tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing cristae structure, preserving electron transport efficiency, and reducing reactive oxygen species production.

Research areas
  • Heart failure with preserved ejection fraction
  • Primary mitochondrial myopathy
  • Age-related muscle dysfunction
  • Dry AMD (ophthalmology)
Considerations
  • Investigational; not FDA-approved.
  • Injection-site reactions are common in trials.
Full SS-31 (Elamipretide) profile →

Trial-evidence rating

Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.

Humanin
Preliminary

Early-stage research; conclusions are tentative.

1 cited study
SS-31 (Elamipretide)
Preliminary

Early-stage research; conclusions are tentative.

1 cited study

Study-by-study comparison

PeptideStudySourceYearSummary
HumaninHumanin: a harbinger of mitochondrial-derived peptidesTrends in Endocrinology & Metabolism2013Reviewed cytoprotective, metabolic, and longevity-relevant signaling.
SS-31 (Elamipretide)Elamipretide in primary mitochondrial myopathy (MMPOWER-3)Neurology2020Did not meet primary endpoints but showed signals in subgroup analyses.

Side-effect & safety grid

Humanin
  • Early-stage research.
  • No approved therapeutic use.
SS-31 (Elamipretide)
  • Investigational; not FDA-approved.
  • Injection-site reactions are common in trials.

Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.

Humanin vs SS-31 (Elamipretide) — Key differences

  • Class: Humanin is classified as Mitochondrial · Neuroprotection, while SS-31 (Elamipretide) is Mitochondrial.
  • Primary research focus: Humaninneuroprotection (alzheimer's models); SS-31 (Elamipretide)heart failure with preserved ejection fraction.
  • Tag: Longevity vs Mitochondrial.

Related comparisons